Home Alzheimer’s Disease Phase 1/2a Data Finds BI-1206 Antibody Restores Response to Rituximab in Patients...

Phase 1/2a Data Finds BI-1206 Antibody Restores Response to Rituximab in Patients With Relapsed Non-Hodgkin Lymphoma

BioInvent International AB recently announced interim data from a phase 1/2a trial of the antibody BI-1206 in combination with rituximab (Rituxan) to treat patients with relapsed or refractory B-cell non-Hodgkin lymphoma (NHL), according to a press release from CASI Pharmaceuticals.

The data suggests that BI-1206, the novel anti-FcγRIIB antibody, restores the response to rituximab, an anti-CD20 monoclonal antibody, for patients with this form of NHL.

“The responses observed in 6 out of 9 patients are very encouraging and clearly suggest that BI-1206 may restore the response to rituximab in patients who have few treatment alternatives,” Martin Welschof, PhD, CEO of BioInvent, said in a press release. “The complete responses we have seen in 2 patients are particularly impressive and indicate that BI-1206 has the potential to significantly improve the lives of [patients with NHL]…

Continue Reading to the Source

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

Lower-Dose Hypofractionated Radiotherapy Schedule Proves Effective for Patients With Locally Advanced Bladder Cancer

Using a hypofractionated schedule of 55 Gy in 20 fractions over 4 weeks to treat patients with locally advanced bladder cancer was noninferior to...

Study Identifies New Biomarker Which Could Predict Response to CD40 Immunotherapy in Pancreatic Cancer

Research published in JCI Insight identified systemic inflammation as a possible resistance mechanism to a CD40–based chemoimmunotherapy in patients with advanced pancreatic cancer.1According to...

Significant Interfacility Variation Found in Implementation of Low-Value Breast Cancer Procedures

A number of facility-level characteristics were associated with the use of low-value breast cancer procedures, and interfacility variation presented an opportunity for formal de-implementation...

KarMMa Trial Results for Ide-Cel in Refractory Myeloma Show Favorable Efficacy

Chimeric antigen receptor (CAR) T-cell therapy with idecabtagene vicleucel (ide-cel) induced responses in almost 75% of patients with multiple myeloma following relpase on multiple...

Recent Comments